2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- manufacturers
- KY19382
-
- $100.00 / 1mg
-
2025-11-10
- CAS:2226664-93-1
- Min. Order:
- Purity: 98.06%
- Supply Ability: 10g
|
| | 2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- Basic information |
| Product Name: | 2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- | | Synonyms: | 2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-;Ky19382;A3051;2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382;Glycogen synthase kinase 3,Beta catenin,β-catenin,GSK-3,KY 19382,inhibit,Wnt,Inhibitor,KY-19382,A 3051,KY19382,A-3051,Glycogen synthase kinase-3;5',6'-Dichloro-3-(methoxyimino)-[2,3'-biindolinylidene]-2'-one;KY19382（A3051）;KY19382, 10 mM in DMSO | | CAS: | 2226664-93-1 | | MF: | C17H11Cl2N3O2 | | MW: | 360.19 | | EINECS: | | | Product Categories: | | | Mol File: | 2226664-93-1.mol | ![2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- Structure](CAS/20200611/GIF/2226664-93-1.gif) |
| | 2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- Chemical Properties |
| density | 1.58±0.1 g/cm3(Predicted) | | solubility | DMSO: Soluble | | pka | 8.80±0.20(Predicted) | | form | Solid | | color | Brown to reddish brown | | InChI | InChI=1S/C17H11Cl2N3O2/c1-24-22-15-8-4-2-3-5-12(8)20-16(15)14-9-6-10(18)11(19)7-13(9)21-17(14)23/h2-7,20H,1H3,(H,21,23) | | InChIKey | PROTUMHDKVZVBW-UHFFFAOYSA-N | | SMILES | N1C2=C(C=C(Cl)C(Cl)=C2)C(=C2C(=NOC)C3=C(N2)C=CC=C3)C1=O |
| | 2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- Usage And Synthesis |
| Uses | KY 19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β. | | in vivo | KY19382 (0.1 mg/kg; i.p. once daily for 2 weeks) delays growth plate senescence in older mice and promotes growth plate maturation in rapidly growing young mice[1].
KY19382 (0.1 mg/kg; i.p. once daily for 10 weeks) significantly increases the length of tibiae in mice[1].
KY19382 (5 mg/kg; i.p.) displays a relatively favorable bioavailability (F=16.74%), showing half-life of 16.20 h and an exposure level of 6,555.79 ng?h/ml[1].
KY19382 (A3051) (25 mg/kg; p.o. once daily for 16 weeks) shows reduction in adipocyte size and anti-inflammatory effects[2].
A3051 (25 mg/kg; p.o. once daily for 5 days) reduces fasting glucose in mice[2].
A3051 (25 mg/kg; p.o. once daily for 3 weeks) reduces the hepatosteatosis in mice[2]. | Animal Model: | C57BL/6 male mice (7-weeks-old or 3-weeks-old)[1] | | Dosage: | 0.1 mg/kg | | Administration: | I.p. once daily for 2 weeks | | Result: | Increased nuclear β-catenin in the growth plate chondrocytes dramatically.
Elevated the height of each growth plate zone and BrdU-positive cells.
Did not affect the cartilage resorption of rapidly growing young mice.
|
| Animal Model: | SD male rats[1] | | Dosage: | 1 mg/kg for i.v. and 5 mg/kg for i.p. (Pharmacokinetic Analysis) | | Administration: | I.v. and i.p. administration | | Result: | I.v.: t1/2=3.33 h; AUC=7832.81 ng?h/mL; CL=0.12 L/h/kg.
I.p.: t1/2=16.20 h; F=16.74%; Cmax=463.37 ng/mL.
|
| | IC 50 | CXXC5-DVL: 19 nM (IC50); GSK3β: 10 nM (IC50) | | References | [1] SEHEE CHOI. CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth.[J]. Life Science Alliance, 2019. DOI: 10.26508/lsa.201800254 |
| | 2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro- Preparation Products And Raw materials |
|